Antiviral management of seasonal and pandemic influenza

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 2, 2006, Pages

  Hayden, Frederick G ^a,c   Pavia, Andrew T ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 315675; AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; PERAMIVIR; PROTEIN INHIBITOR; PROTEIN M2; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISABILITY; DISEASE DURATION; DRUG EFFICACY; DRUG SENSITIVITY; FUNCTIONAL ASSESSMENT; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA A; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; UNITED STATES; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MICE; NEURAMINIDASE; OSELTAMIVIR; RIMANTADINE; SEASONS; ZANAMIVIR;

EID: 33750313978     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507552     Document Type: Review

References (57)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
2. Terebuh P, Uyeki T, Kukuda K. Impact of influenza on young children and the shaping of United States influenza vaccine policy. Pediatr Infect Dis J 2003; 22(Suppl):S231-5.
3. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303:41-4.
4. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kort AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14:327-32.
5. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-23.
6. Kim CU, Xiaowu C, Mendel DB. Neuraminidase inhibitors as anti-influenza virus agents. Antivir Chem Chemother 1999; 10:141-54.
7. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307:580-4.
8. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224-8.
9. Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969; 2:1026-8.
10. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantidine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
11. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359-66.
12. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-5.
13. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343:1282-9.
14. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186:1582-8.
15. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285:748-54.
16. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-9.
17. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-43.
18. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-31.
19. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283:1016-24.
20. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33.
21. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005; 24:931-2.
22. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
23. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367:303-13.
24. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden FG. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72.
25. Kaiser L, Keene ON, Hammond JMJ, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-40.
26. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.
27. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005; 21:761-8.
28. Nordstrom BL, Zhu S, Smith JR. Reduction of influenza complications following oseltamivir use [abstract S18-2]. In: Proceedings and abstracts of the Second European Influenza Conference (St. Julian's, Malta). St. Julian's, Malta: European Scientific Working Group on Influenza, 2005.
29. Rothberg MB, Bonner AB, Rajab MH, Kim HS, Stechenberg BW, Rose DN. Effects of local variation, specialty, and beliefs on antiviral prescribing for influenza. Clin Infect Dis 2006; 42:95-9.
30. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-9.
31. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. jAMA 1979; 241:1003-7.
32. Hayden FG. Antivirals for pandemic influenza. J Infect Dis 1997; 176 (Suppl):S56-61.
33. Ferguson NM, Cummings DAT, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437:209-14.
34. Longini IM Jr, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309:1083-7.
35. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occurring influenza A7USSR/77 H1N1. JAMA 1981; 245:1128-31.
36. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005; 11:1355-62.
37. Leneva IR, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza virus. Antiviral Res 2000; 48:101-15.
38. Yen H-L, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192:665-72.
39. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
40. Chan PKS. Outbreak of avian influenza A(HSN1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002; 34(Suppl 2):S58-64.
41. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991; 164:969-72.
42. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81.
43. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantine resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4.
44. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc London B Biol Sci 2001; 356:1895-7.
45. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
46. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55:i5-21.
47. Gubareva L, Hayden FG. M2 and neuraminidase inhibitors: anti-influenza activity, mechanisms of resistance, and clinical effectiveness. In: Kawaoka Y, ed. Influenza virology. Hethersett, Norwich, UK: Horizon Scientific Press, 2006:169-201.
48. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
49. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of a drug-resistant H5N1 virus. Nature 2005; 437:1108.
50. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-30.
51. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-20.
52. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41:742-50.
53. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005; 80:156.
54. De Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
55. Hayden FG, Douglas RG, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980; 18:536-41.
56. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-90.
57. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-20.